Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH1 | O75874 | 2/20 | 0.34 |
| ▸ | IDH2 | P48735 | 1/20 | 0.33 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.32 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.32 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
| ▸ | APLNR | P35414 | 1/20 | 0.31 |
| ▸ | HPGDS | O60760 | 1/20 | 0.30 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13705258 | 1.00 | IDH1 (0.34) | IDH1IDH2ABHD6DAGLAHDAC8 | |
| SCHEMBL4296669 | 0.94 | HTR1A (0.30) | — | |
| SCHEMBL4284686 | 0.94 | HTR1A (0.30) | — | |
| SCHEMBL13705255 | 0.89 | USP30 (0.33) | ABHD6DAGLAAPLNRHPGDSUSP30 | |
| SCHEMBL13705260 | 0.89 | USP30 (0.33) | ABHD6DAGLAAPLNRHPGDSUSP30 | |
| SCHEMBL13705263 | 0.88 | IDH1 (0.36) | IDH1IDH2ABHD6DAGLAAPLNR | |
| Hydrochloric Acid SCHEMBL4285131 | 0.86 | USP19 (0.33) | — | |
| Hydrochloric Acid SCHEMBL4287483 | 0.86 | USP19 (0.33) | — | |
| Hydrochloric Acid SCHEMBL4281611 | 0.86 | USP19 (0.33) | — | |
| SCHEMBL13705297 | 0.85 | APLNR (0.34) | ABHD6DAGLAAPLNRHPGDSUSP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227560-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-10 | — | — | US | disclosed |
| US-20090156612-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156612-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | IDH1 112/4885IDH2 155/4885ABHD6 3736/4885 |
| US-20090227560-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | IDH1 112/4885IDH2 155/4885ABHD6 3736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.